FDA postpones panel for Glaxo's COPD drug as snowstorm advances
March 5 (Reuters) - The U.S. Food and Drug Administration said on Tuesday it has postponed a meeting of outside advisers scheduled for March 7 to review a drug developed by GlaxoSmithKline Plc and Theravance Inc for chronic obstructive pulmonary disease (COPD).
The agency did not officially give a reason for the postponement but it comes as a major snowstorm bears down on the Northeastern United States, including Washington D.C., where the panelists were due to meet.
The agency said it would post briefing materials related to the drug, to be called Breo if approved in the United States, no later than two days before the next meeting, once announced.
- Sunken Korea ferry relatives give DNA swabs to help identify dead |
- Vice-principal of South Korea school in ferry disaster commits suicide |
- Special Report: How the U.S. made its Putin problem worse
- Death toll climbs to at least 13 in worst tragedy on Everest |
- All 338 Korean students, teachers rescued from sinking ferry - school official